2023 年第 8 期 第 18 卷

美沙拉秦联合昂丹司琼对溃疡性结肠炎患者肠黏膜屏障功能及炎症因子水平的影响

Effect of mesalazine combined with ondansetron on intestinal mucosal barrier function and inflammatory factor level in patients with ulcerative colitis

作者：蒋世芳1曹立军1贺学强1罗琼2陈甚均1戴璞1李祖鹏1罗燕英1

英文作者：Jiang Shifang1 Cao Lijun1 He Xueqiang1 Luo Qiong2 Chen Shenjun1 Dai Pu1 Li Zupeng1 Luo Yanying1

单位：1中国人民解放军联勤保障部队第九二四医院消化内科，桂林530001；2广西壮族自治区桂林市人民医院彩超室，桂林530001

英文单位：1Department of Gastroenterology 924th Hospital of the Joint Service Support Force of the Chinese People′s Liberation Army Guilin 530001 China; 2Color Doppler Ultrasound Room Guilin People′s Hospital Guangxi Zhuang Autonomous Region Guilin 530001 China

关键词：溃疡性结肠炎；美沙拉秦；昂丹司琼；肠黏膜屏障；炎症因子

英文关键词：Ulcerativecolitis；Mesalamine；Ondansetron；Intestinalmucosalbarrier；Inflammatoryfactor

• 摘要：

• 目的 探讨美沙拉秦联合昂丹司琼对溃疡性结肠炎（UC）患者肠黏膜屏障功能及炎症因子水平的影响。方法 选取2019年4月至2022年4月在中国人民解放军联勤保障部队第九二四医院消化内科治疗的80例UC患者，按随机数字表法分为观察组和对照组，各40例。对照组给予美沙拉秦治疗；观察组在对照组基础上给予昂丹司琼治疗。比较2组治疗前后肠黏膜屏障功能指标［二胺氧化酶(DAO)、D-乳酸］、炎症因子［肿瘤坏死因子α（TNF-α）、白细胞介素17（IL-17）、IL-23］水平，治疗2、4、8周肠黏膜愈合率和临床疗效。结果 治疗后，观察组DAO、D-乳酸、TNF-α、IL-17、IL-23水平均低于对照组（均P＜0.05）。观察组治疗2、4、8周肠黏膜愈合率均高于对照组（均P＜0.05）。观察组治疗总有效率高于对照组［95.0%(38/40)比67.5%(27/40)］（P=0.002）。结论 对UC患者采用美沙拉秦联合昂丹司琼进行治疗，可改善肠黏膜屏障功能，降低炎症因子水平，提高肠黏膜愈合率和治疗有效率。

• Objective To investigate the effect of mesalazine combined with ondansetron on intestinal mucosal barrier function and inflammatory factor level in patients with ulcerative colitis (UC). Methods  From April 2019 to April 2022, 80 patients with UC admitted to Department of Gastroenterology, 924th Hospital of the Joint Service Support Force of the Chinese People′s Liberation Army were selected. Patients were divided into observation group and control group according to random number table method, with 40 cases in each group. The control group was treated with mesalazine. The observation group was treated with ondansetron on the basis of control group. The intestinal mucosal barrier function indexes ［diamine oxidase (DAO), D-lactic acid］, inflammatory factors ［tumor necrosis factor-α(TNF-α), interleukin-17 (IL-17) and IL-23］ levels before and after treatment were compared between the two groups, and the intestinal mucosal healing rate at 2, 4 and 8 weeks of treatment and the clinical efficacy were compared between the two groups. Results After treatment, levels of DAO, D-lactic acid, TNF-α, IL-17 and IL-23 in observation group were lower than those in control group (all P＜0.05). The intestinal mucosal healing rate in observation group was higher than that in control group at 2, 4 and 8 weeks of treatment (all P＜0.05). The total effective rate in observation group was higher than that in control group ［95.0%(38/40) vs 67.5%(27/40)］(P=0.002). Conclusion Mesalazine combined with ondansetron in the treatment of patients with UC can improve intestinal mucosal barrier function, reduce the levels of inflammatory factors, improve the rate of intestinal mucosal healing and the effective rate of treatment.